[89Zr]Zr-girentuximab PET-CT imaging to diagnose, characterize, and differentiate clear-cell renal cell carcinoma

Chadi Hage Chehade; Georges Gebrael; Neeraj Agarwal

doi:10.1016/j.medj.2024.10.003

[⁸⁹Zr]Zr-girentuximab PET-CT imaging to diagnose, characterize, and differentiate clear-cell renal cell carcinoma

Med. 2024 Nov 8;5(11):1345-1347. doi: 10.1016/j.medj.2024.10.003.

Authors

Chadi Hage Chehade¹, Georges Gebrael¹, Neeraj Agarwal²

Affiliations

¹ Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
² Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address: [email protected].

PMID: 39520979
DOI: 10.1016/j.medj.2024.10.003

Abstract

In the phase 3 ZIRCON trial, [⁸⁹Zr]Zr-girentuximab positron emission tomography-computed tomography (PET-CT) detected the presence of clear-cell renal cell carcinoma (ccRCC) with a sensitivity of 86% and a specificity of 87% in patients with an indeterminate renal mass undergoing nephrectomy.¹ This imaging technique could be a promising tool that could revolutionize the management of small renal masses (SRMs) and ccRCC.

MeSH terms

Aged
Antibodies, Monoclonal
Carcinoma, Renal Cell* / diagnostic imaging
Carcinoma, Renal Cell* / pathology
Diagnosis, Differential
Female
Humans
Kidney Neoplasms* / diagnostic imaging
Kidney Neoplasms* / pathology
Male
Middle Aged
Positron Emission Tomography Computed Tomography* / methods
Radioisotopes
Radiopharmaceuticals / chemistry
Sensitivity and Specificity
Zirconium*

Substances

Zirconium
G250 monoclonal antibody
Zirconium-89
Radiopharmaceuticals
Radioisotopes
Antibodies, Monoclonal